Vagus Nerve Stimulation Market Size, Share | Report 2022-2030
The global vagus nerve stimulation market was valued at USD 673.02 million in 2021 and it is predicted to surpass around USD 1.59 billion by 2030 with a CAGR of 10.03% from 2022 to 2030.
Market Synopsis
Vagus Nerve Stimulation devices are used for the treatment of chronic conditions, such as epilepsy and depression, which involves stimulation of the vagus nerve with electrical impulses. VNS consists of two major components: a vagus pacemaker and an electrode. Epilepsy is a chronic disease, and most epileptic patients use medications and dietary restrictions to control their seizures. However, in about 30% of the cases, medications fail to curb the seizures, thereby driving patients to resort to treatment via a VNS device. The use of a VNS device reduces the occurrence of epileptic seizures by 50%. The high efficacy exhibited by these devices in treating epilepsy and their application in the treatment of diseases such as chronic depression are some of the major factors expected to drive the market over the next 6 years.
Scope of The Report
| Report Coverage | Details |
| Market Size in 2021 | USD 673.02 million |
| Revenue Forecast by 2030 | USD 1.59 billion |
| Growth rate from 2022 to 2030 | CAGR of 10.03% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segmentation | Application, Product, Biomaterial, End User, Region |
| Companies Covered |
Cyberonics, Neurospace, electroCore, Medtronic, Cerebral Rx, LivaNova LLC,MicroTransponder, Inc., and NERVANA LLC among others |
Market Influencer
The growing incidence of neurological disorders such as epilepsy, depression, and migraine as well as the rising adoption of minimally invasive neurosurgical procedures are the key growth drivers for the global vagus nerve stimulation market. According to WHO in 2019, over 50 million people in the world have epilepsy. Although epilepsy can be controlled using medication, VNS therapy can be used as an add-on treatment to control seizures. Similarly, as per the American Headache Society, migraine is one of the major causes of disability in the U.S. and the third most prevalent disease in the world. Also, as per the Migraine Research Foundation in 2019, migraine affects nearly 39 million Americans and about 1 billion people worldwide. Thus, the increasing prevalence of chronic conditions, such as epilepsy and migraine, is expected to contribute to the market growth during the forecast period.
Furthermore, an increasing number of approvals and new product launches are expected to further drive the market growth over the forecast period. The introduction of new and innovative products by key market players is fuelling the demand and adoption of VNS devices in the global market. For instances,
These technological advancements are expected to boost the Vagus Nerve Stimulation market growth over the forecast period. Key players operating in the vagus nerve stimulation market include Cyberonics, Neurospace, electroCore, Medtronic, Cerebral Rx, LivaNova LLC,MicroTransponder, Inc., and NERVANA LLC among others. Moreover, the FDA has approved an implantable VNS for the treatment of epilepsy and depression. Additionally, a new non-invasive VNS device that does not require surgical implantation has been approved in Europe to treat epilepsy, depression, and pain.
However, device-related technical failures and complications, along with the high cost of these devices and their maintenance is expected to shrink the market growth during the forecast period.
Market Segmentation
By Application
By Product
By Biomaterial
By End User
By Region
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Vagus Nerve Stimulation Market
5.1. COVID-19 Landscape: Vagus Nerve Stimulation Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Vagus Nerve Stimulation Market, By Application
8.1. Vagus Nerve Stimulation Market, by Application, 2022-2030
8.1.1. Depression
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Epilepsy
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Migraine
8.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Vagus Nerve Stimulation Market, By Product
9.1. Vagus Nerve Stimulation Market, by Product, 2022-2030
9.1.1. Implantable VNS Devices
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. External VNS Devices
9.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Vagus Nerve Stimulation Market, By Biomaterial
10.1. Vagus Nerve Stimulation Market, by Biomaterial, 2022-2030
10.1.1. Polymerics
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Metallics
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Ceramics
10.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Vagus Nerve Stimulation Market, By End User
11.1. Vagus Nerve Stimulation Market, by End User, 2022-2030
11.1.1. Hospitals
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Ambulatory Surgical Centers (ASCS)
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Others
11.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Vagus Nerve Stimulation Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Application (2017-2030)
12.1.2. Market Revenue and Forecast, by Product (2017-2030)
12.1.3. Market Revenue and Forecast, by Biomaterial (2017-2030)
12.1.4. Market Revenue and Forecast, by End User (2017-2030)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Application (2017-2030)
12.1.5.2. Market Revenue and Forecast, by Product (2017-2030)
12.1.5.3. Market Revenue and Forecast, by Biomaterial (2017-2030)
12.1.5.4. Market Revenue and Forecast, by End User (2017-2030)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Application (2017-2030)
12.1.6.2. Market Revenue and Forecast, by Product (2017-2030)
12.1.6.3. Market Revenue and Forecast, by Biomaterial (2017-2030)
12.1.6.4. Market Revenue and Forecast, by End User (2017-2030)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Application (2017-2030)
12.2.2. Market Revenue and Forecast, by Product (2017-2030)
12.2.3. Market Revenue and Forecast, by Biomaterial (2017-2030)
12.2.4. Market Revenue and Forecast, by End User (2017-2030)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Application (2017-2030)
12.2.5.2. Market Revenue and Forecast, by Product (2017-2030)
12.2.5.3. Market Revenue and Forecast, by Biomaterial (2017-2030)
12.2.5.4. Market Revenue and Forecast, by End User (2017-2030)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Application (2017-2030)
12.2.6.2. Market Revenue and Forecast, by Product (2017-2030)
12.2.6.3. Market Revenue and Forecast, by Biomaterial (2017-2030)
12.2.6.4. Market Revenue and Forecast, by End User (2017-2030)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Application (2017-2030)
12.2.7.2. Market Revenue and Forecast, by Product (2017-2030)
12.2.7.3. Market Revenue and Forecast, by Biomaterial (2017-2030)
12.2.7.4. Market Revenue and Forecast, by End User (2017-2030)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Application (2017-2030)
12.2.8.2. Market Revenue and Forecast, by Product (2017-2030)
12.2.8.3. Market Revenue and Forecast, by Biomaterial (2017-2030)
12.2.8.4. Market Revenue and Forecast, by End User (2017-2030)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Application (2017-2030)
12.3.2. Market Revenue and Forecast, by Product (2017-2030)
12.3.3. Market Revenue and Forecast, by Biomaterial (2017-2030)
12.3.4. Market Revenue and Forecast, by End User (2017-2030)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Application (2017-2030)
12.3.5.2. Market Revenue and Forecast, by Product (2017-2030)
12.3.5.3. Market Revenue and Forecast, by Biomaterial (2017-2030)
12.3.5.4. Market Revenue and Forecast, by End User (2017-2030)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Application (2017-2030)
12.3.6.2. Market Revenue and Forecast, by Product (2017-2030)
12.3.6.3. Market Revenue and Forecast, by Biomaterial (2017-2030)
12.3.6.4. Market Revenue and Forecast, by End User (2017-2030)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Application (2017-2030)
12.3.7.2. Market Revenue and Forecast, by Product (2017-2030)
12.3.7.3. Market Revenue and Forecast, by Biomaterial (2017-2030)
12.3.7.4. Market Revenue and Forecast, by End User (2017-2030)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Application (2017-2030)
12.3.8.2. Market Revenue and Forecast, by Product (2017-2030)
12.3.8.3. Market Revenue and Forecast, by Biomaterial (2017-2030)
12.3.8.4. Market Revenue and Forecast, by End User (2017-2030)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Application (2017-2030)
12.4.2. Market Revenue and Forecast, by Product (2017-2030)
12.4.3. Market Revenue and Forecast, by Biomaterial (2017-2030)
12.4.4. Market Revenue and Forecast, by End User (2017-2030)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Application (2017-2030)
12.4.5.2. Market Revenue and Forecast, by Product (2017-2030)
12.4.5.3. Market Revenue and Forecast, by Biomaterial (2017-2030)
12.4.5.4. Market Revenue and Forecast, by End User (2017-2030)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Application (2017-2030)
12.4.6.2. Market Revenue and Forecast, by Product (2017-2030)
12.4.6.3. Market Revenue and Forecast, by Biomaterial (2017-2030)
12.4.6.4. Market Revenue and Forecast, by End User (2017-2030)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Application (2017-2030)
12.4.7.2. Market Revenue and Forecast, by Product (2017-2030)
12.4.7.3. Market Revenue and Forecast, by Biomaterial (2017-2030)
12.4.7.4. Market Revenue and Forecast, by End User (2017-2030)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Application (2017-2030)
12.4.8.2. Market Revenue and Forecast, by Product (2017-2030)
12.4.8.3. Market Revenue and Forecast, by Biomaterial (2017-2030)
12.4.8.4. Market Revenue and Forecast, by End User (2017-2030)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Application (2017-2030)
12.5.2. Market Revenue and Forecast, by Product (2017-2030)
12.5.3. Market Revenue and Forecast, by Biomaterial (2017-2030)
12.5.4. Market Revenue and Forecast, by End User (2017-2030)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Application (2017-2030)
12.5.5.2. Market Revenue and Forecast, by Product (2017-2030)
12.5.5.3. Market Revenue and Forecast, by Biomaterial (2017-2030)
12.5.5.4. Market Revenue and Forecast, by End User (2017-2030)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Application (2017-2030)
12.5.6.2. Market Revenue and Forecast, by Product (2017-2030)
12.5.6.3. Market Revenue and Forecast, by Biomaterial (2017-2030)
12.5.6.4. Market Revenue and Forecast, by End User (2017-2030)
Chapter 13. Company Profiles
13.1. Cyberonics
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Neurospace
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. electroCore
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Medtronic
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Cerebral Rx
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. LivaNova LLC
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. MicroTransponder, Inc.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. NERVANA LLC
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. others
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers